Flk-1, Human, ELISA Kit, Quantikine (96well) <VEGF Receptor 2, ELISA Kit>

データシート※最新のデータシートでない場合があります

• 商品コード：DVR200
• メーカー：RSD
• 包装：1kit
• 価格： ¥116,000
• 在庫：無(未発注)

マイリストに追加 マイリストに追加済

• No.： 1
• 文献情報：
  Hu Q et al. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004 May;100(9):1884-91
  Hu Q et al
  2004/01/01
  
• 備考：
  Sample Type: Plasma (EDTA)
• 参照：
  

• No.： 2
• 文献情報：
  Saitou Y et al. Serum vascular endothelial growth factor-receptor 1 during liver regeneration. J. Hepatol. 2004 Jul;41(1):170-1
  Saitou Y et al
  2004/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 3
• 文献情報：
  Abadie Y et al. Decreased VEGF concentration in lung tissue and vascular injury during ARDS. Eur. Respir. J. 2005 Jan;25(1):139-46
  Abadie Y et al
  2005/01/01
  
• 備考：
  Sample Type: Homogenized Tissue - Protocol Included
• 参照：
  

• No.： 4
• 文献情報：
  Asikainen TM et al. Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. Free Radic. Biol. Med. 2005 Apr;38(8):1002-13
  Asikainen TM et al
  2005/01/01
  
• 備考：
  Sample Type: Cell Lysates,Cell Supernates
• 参照：
  

• No.： 5
• 文献情報：
  Tseng JJ et al. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta 2006 Jan;27(1):70-8
  Tseng JJ et al
  2006/01/01
  
• 備考：
  human placenta
• 参照：
  

• No.： 6
• 文献情報：
  Giles FJ et al. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk. Res. 2006 Jul;30(7):801-11
  Giles FJ et al
  2006/01/01
  
• 備考：
  Species: Human, Sample type: Plasma (Heparin)
• 参照：
  

• No.： 7
• 文献情報：
  Wallner W et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin. Sci. 2007 Jan;112(1):51-7
  Wallner W et al
  2007/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 8
• 文献情報：
  Boulanger E et al. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int. 2007 Jan;71(2):126-33
  Boulanger E et al
  2007/01/01
  
• 備考：
  Sample Type: Cell Supernates
• 参照：
  

• No.： 9
• 文献情報：
  Batchelor TT et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007 Jan;11(1):83-95
  Batchelor TT et al
  2007/01/01
  
• 備考：
  Sample Type: Plasma (EDTA)
• 参照：
  

• No.： 10
• 文献情報：
  Norden-Zfoni A et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin. Cancer Res. 2007 May;13(9):2643-50
  Norden-Zfoni A et al
  2007/01/01
  
• 備考：
  Species: Human, Sample type: Plasma (EDTA)
• 参照：
  

• No.： 11
• 文献情報：
  Saltz LB et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 2007 Oct;25(30):4793-9
  Saltz LB et al
  2007/01/01
  
• 備考：
  Species: Human, Sample type: Plasma (Not Specified)
• 参照：
  

• No.： 12
• 文献情報：
  Burstein HJ et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008 Apr;26(11):1810-6
  Burstein HJ et al
  2008/01/01
  
• 備考：
  Species: Human, Application: Plasma (Not Specified)
• 参照：
  

• No.： 13
• 文献情報：
  Ezhilarasan R et al. The hemopexin domain of MMP-9 inhibits angiogenesis and retards the growth of intracranial glioblastoma xenograft in nude mice. Int. J. Cancer 2009 Jan;124(2):306-15
  Ezhilarasan R et al
  2009/01/01
  
• 備考：
  Sample Type: Cell Lysates
• 参照：
  

• No.： 14
• 文献情報：
  Sallinen H et al. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol. Ther. 2009 Feb;17(2):278-84
  Sallinen H et al
  2009/01/01
  
• 備考：
  Sample Type: Plasma (Not Specified)
• 参照：
  

• No.： 15
• 文献情報：
  Bourlev V et al. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis. Fertil. Steril. 2010 Jun;94(1):52-7
  Bourlev V et al
  2010/01/01
  
• 備考：
  Sample Type: Peritoneal Fluid,Serum
• 参照：
  

• No.： 16
• 文献情報：
  Zhu AX et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J. Clin. Oncol. 2009 Jun;27(18):3027-35
  Zhu AX et al
  2009/01/01
  
• 備考：
  Sample Type: Plasma (EDTA)
• 参照：
  

• No.： 17
• 文献情報：
  Brookes K et al. Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. Br. J. Cancer 2010 May;102(10):1524-32
  Brookes K et al
  2010/01/01
  
• 備考：
  Sample Type: Plasma (EDTA)
• 参照：
  

• No.： 18
• 文献情報：
  Konings IR et al. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours. Br. J. Cancer 2010 Sep;103(7):987-92
  Konings IR et al
  2010/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 19
• 文献情報：
  Farace F et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br. J. Cancer 2011 Mar;104(7):1144-50
  Farace F et al
  2011/01/01
  
• 備考：
  Sample Type: Plasma (Heparin)
• 参照：
  

• No.： 20
• 文献情報：
  Loupakis F et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br. J. Cancer 2011 Apr;104(8):1262-9
  Loupakis F et al
  2011/01/01
  
• 備考：
  Sample Type: Plasma (Not Specified)
• 参照：
  

• No.： 21
• 文献情報：
  de Groot JF et al. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin. Cancer Res. 2011 Jul;17(14):4872-81
  de Groot JF et al
  2011/01/01
  
• 備考：
  Sample Type: Plasma (EDTA),Urine
• 参照：
  

• No.： 22
• 文献情報：
  Landt S et al. Prognostic significance of angiogenic factors in uterine cervical cancer. Anticancer Res. 2011 Aug;31(8):2589-95
  Landt S et al
  2011/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 23
• 文献情報：
  Harmon CS et al. Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 2011;9:120
  Harmon CS et al
  2011/01/01
  
• 備考：
  Sample Type: Plasma (Heparin)
• 参照：
  

• No.： 24
• 文献情報：
  Dubois SG et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children&quot;s oncology group study. Clin. Cancer Res. 2011 Aug;17(15):5113-22
  Dubois SG et al
  2011/01/01
  
• 備考：
  Sample Type: Plasma (Not Specified)
• 参照：
  

• No.： 25
• 文献情報：
  Sleijfer S et al. Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. Br. J. Cancer 2012 Aug;107(4):639-45
  Sleijfer S et al
  2012/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 26
• 文献情報：
  Widemann BC et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children&quot;s Oncology Group Phase I Consortium report. Clin. Cancer Res. 2012 Nov;18(21):6011-22
  Widemann BC et al
  2012/01/01
  
• 備考：
  Sample Type: Plasma
• 参照：
  

• No.： 27
• 文献情報：
  Somlo G et al. Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004. Clin. Cancer Res. 2013 Apr;19(7):1884-93
  Somlo G et al
  2013/01/01
  
• 備考：
  Sample Type: Plasma
• 参照：
  

• No.： 28
• 文献情報：
  Abu El-Asrar AM et al. Angiogenic and vasculogenic factors in the vitreous from patients with proliferative diabetic retinopathy. J Diabetes Res 2013;2013:539658
  Abu El-Asrar AM et al
  2013/01/01
  
• 備考：
  Sample Type: Cell Lysates
• 参照：
  

• No.： 29
• 文献情報：
  Briasoulis E et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer 2013;13:263
  Briasoulis E et al
  2013/01/01
  
• 備考：
  Sample Type: Plasma
• 参照：
  

• No.： 30
• 文献情報：
  Necchi A et al. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. Br. J. Cancer 2014 Jan;110(1):26-33
  Necchi A et al
  2014/01/01
  
• 備考：
  Sample Type: Plasma
• 参照：
  

• No.： 31
• 文献情報：
  Sallinen H et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer 2014;14:696
  Sallinen H et al
  2014/01/01
  
• 備考：
  Sample Type: Serum
• 参照：
  

• No.： 32
• 文献情報：
  Salazar R et al. A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. BMC Cancer 2015;15:60
  Salazar R et al
  2015/01/01
  
• 備考：
  Sample Type: Plasma
• 参照：
  

• No.： 33
• 文献情報：
  J端rgensmeier JM et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br. J. Cancer 2013 Apr;108(6):1316-23
  J端rgensmeier JM et al
  2013/01/01
  
• 備考：
  Sample Type: Plasma
• 参照：
  

• No.： 34
• 文献情報：
  S叩nchez Ram鱈rez J et al. Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. BMC Immunol. 2017 Jul;18(1):39
  S叩nchez Ram鱈rez J et al
  2017/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 35
• 文献情報：
  Zarychta E et al. Anti-angiogenic efficacy in invasive breast carcinoma patients depends on clinicopathological determinants. Adv Med Sci 2019 Feb;64(2):216-223
  Zarychta E et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 36
• 文献情報：
  Kalender G et al. Kinetics of circulating endothelial progenitor cells in patients undergoing carotid artery surgery. Ther Clin Risk Manag 2016;12:1841-1847
  Kalender G et al
  2016/01/01
  
• 備考：
  
• 参照：
  

• No.： 37
• 文献情報：
  Panta S et al. Low grade inflammation inhibits VEGF induced HUVECs migration in p53 dependent manner. Biochem. Biophys. Res. Commun. 2017 02;483(2):803-809
  Panta S et al
  2017/01/01
  
• 備考：
  
• 参照：
  

• No.： 38
• 文献情報：
  Takaya H et al. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma. BMC Gastroenterol 2019 Oct;19(1):167
  Takaya H et al
  2019/01/01
  
• 備考：
  
• 参照：
  

• No.： 39
• 文献情報：
  Waszczykowska A et al. Matrix Metalloproteinases MMP-2 and MMP-9, Their Inhibitors TIMP-1 and TIMP-2, Vascular Endothelial Growth Factor and sVEGFR-2 as Predictive Markers of Ischemic Retinopathy in Patients with Systemic Sclerosis-Case Series Report. Int
  Waszczykowska A et al
  2020/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 40
• 文献情報：
  Fountzilas C et al. A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma. Br J Cancer 2020 03;122(7):963-970
  Fountzilas C et al
  2020/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 41
• 文献情報：
  Zilberman L et al. Residual alterations of cardiac and endothelial function in patients who recovered from Takotsubo cardiomyopathy. Clin Cardiol 2021 Jun;44(6):797-804
  Zilberman L et al
  2021/01/01
  
• 備考：
  Species: Human
• 参照：
  

• No.： 42
• 文献情報：
  Dong D et al. Hyperoxia sensitizes hypoxic HeLa cells to ionizing radiation by downregulating HIF&#x2011;1&#x3B1; and VEGF expression. Mol Med Rep 2021 01;23(1)
  Dong D et al
  2021/01/01
  
• 備考：
  Species: Human
• 参照：